Relief for Future Mothers: Long-Awaited Morning Sickness Medication Finally Coming to Japan
Nearly a decade after its approval in the United States and widespread use in over 40 countries, a dedicated morning sickness medication is finally set to be introduced in Japan. Mochida Pharmaceutical has announced a contract with a Canadian firm to begin clinical trials, aiming for a domestic launch by 2030. The news has sparked a massive wave of reactions on social media. For years, Japan has grappled with the issue of "drug loss"—a phenomenon where new medications approved abroad remain unavailable domestically. Despite the long-standing track record of this morning sickness drug in the U.S., its absence in Japan led many online commenters to criticize the delay as a reflection of a societal mindset that "women should naturally endure suffering" during pregnancy. Following Mochida Pharmaceutical's announcement, former patients who suffered from severe morning sickness (hyperemesis gravidarum) shared harrowing accounts of their experiences. "It was so pa...